OBJECTIVES: To define local risk factors and outcomes for bacteremia with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) at a tertiary hospital in New Zealand. METHODS: Patients with ESBL-E bacteremia were compared to matched control patients with non-ESBL-producing Enterobacteriaceae bacteremia. Patients were matched by onset of bacteremia (community vs. hospital), site of blood culture collection (peripheral vs. via central line), and infecting organism species. RESULTS: Forty-four cases with matched controls were included. Eight- and 30-day mortality was higher in cases than controls (27% vs. 7%; p=0.011 and 34% vs. 11%, p=0.011). Twenty-one cases (48%) were community-onset. Community-onset cases were associated with urinary tract infection, whereas hospital-onset cases were associated with central line infection, intensive care admission, and Enterobacter cloacae. Independent risk factors for ESBL-E bacteremia were fluoroquinolone exposure (odds ratio (OR) 6.56, 95% confidence interval (CI) 1.79-24), first-generation cephalosporin exposure (OR 12.3, 95% CI 1.01-148), and previously-known colonization with ESBL-E (OR 46.2, 95% CI 3.45-619). CONCLUSIONS: The association with fluoroquinolone exposure suggests that measures to reduce unnecessary use may be an effective preventative strategy. Known colonization with ESBL-E is a strong risk factor for ESBL-E bacteremia, and colonization status should be taken into consideration when choosing empirical therapy.
No takes yet. Share an insight, caveat, or question.
Freeman et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: